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ABSTRACT
Objectives: Sexual dysfunction was reported to compromise the quality of life in childhood cancer survivors. The aim of 
our study was to evaluate the reproductive health in long-term pediatric cancer survivors by conducting a crosscut survey. 
Material and methods: Childhood cancer survivors over 18 years of age, who were in remission for more than 5 years, 
were invited to complete a gender-specific questionnaire surveying on their reproductive health. Demographic and treat-
ment data were retrieved from their medical records. Treatment modalities were reviewed for its potential gonadotoxicity. 
Results: 34 (17 males and 17 females, respectively) from 346 addressed survivors (9.8%) completed the questionnaire. Me-
dian age and follow-up after diagnosis was 27 (18–35) and 14 (3–25) years, respectively. Some respondents reported sexual 
concerns: 11.8% males experienced problems with penetration, two males (11.8%) who underwent semen analysis were 
found to be azoospermic. Similarly, 11.8% females reported delayed puberty, the average age of menarche was 14 (12–17) 
years, 29.4% females reported irregular menstrual cycles. Cyclophosphamide equivalent dose (CED) differed significantly 
between the patients treated for leukemia, lymphoma and solid tumors (3000 vs 4352 vs 6660 mg/m2, respectively, p = 0.014). 
Conclusions: Low prevalence of sexual dysfunction, fertility related disorders or delayed puberty in childhood cancer 
survivors was found. However, the results should be interpreted with caution taking into account a low response rate. 
Key words: late effects; long-term survivors; pediatric cancer; reproductive health; sexual dysfunction
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InTROduCTIOn
Over the last few decades, a long-term survival rate after 
pediatric cancer has improved dramatically and nowadays 
exceeds 80% in most European countries [1]. High cure rates 
imply a constantly growing population of childhood cancer 
survivors. As a consequence, research activities are focused 
not only on overcoming  resistant malignancies but also on 
the well-being of the cured persons who are at the risk for 
frailty, and suboptimal quality of life [2].
A healthy reproductive system is a cornerstone of the 
quality of life in young adult survivors. Sexual dysfunction 
was reported to be one of the most important side effects of 
pediatric cancer treatment [3]. Treatment intensity depends 
on cancer type, localization, spread of the disease (metas-
tases) and other risk factors. Most patients are exposed 
to combined treatment including chemotherapy, surgery, 
radiotherapy, less frequently high-dose chemotherapy prior 
to hematopoietic stem cell transplantation and the immune 
therapy. All the approaches, used separately or in combina-
tion, could potentially have an adverse long-term effect on 
fertility [4, 5]. It is crucial to inform every patient (parents or 
guardians in pediatric setting) about the potential adverse 
effect of cancer treatment on the reproductive health and 
options for fertility preservation. The majority of childhood 
cancer survivors perceive they had not been provided suf-
ficient information about reproductive health and had never 
underwent fertility testing [6, 7].
Studies have shown that in females chemotherapy 
regimens containing high-dose alkylating agents and ab-
dominal/pelvic radiotherapy affected the gonadal function, 
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and were associated with delayed puberty, premature ovar-
ian insufficiency and follicular atresia, premature meno-
pause and infertility [8]. In males, infertility was reported to 
be related to the use of alkylating agents, testicular radia-
tion, or cranial irradiation [4]. Certain concomitant chemo-
therapy agents such as cisplatin, carboplatin, increase the 
risk of infertility in childhood cancer survivors [9–11]. 
Cumulative exposure to alkylating agents can be quan-
tified using the cyclophosphamide equivalent dose (CED), 
as described by Green et al. [12] that compares the drugs 
based on the hematological toxicity. The adoption of the 
CED allows evaluation of the relationship between hemato-
logical toxicity and alkylating agent related late outcomes, 
such as infertility. The advantage of the CED is its deriva-
tion from actual drug doses rather than dependence on 
a drug dose distribution specific to a single population [12]. 
CED  ≥  4000 mg/m2 is associated with a risk of infertility, 
while CED ≥ 8000 mg/m2 is most likely to cause infertility 
leading to premature ovarian insufficiency in females [13] 
and increased chance of oligospermia and azoospermia in 
males [14].
The purpose of our study was to evaluate reproductive 
health in pediatric cancer survivors who were in a long-term 
remission and were in reproductive age. The research aimed 
at elucidating personal perception of the study participants 
with regard to their reproductive health, thus a surveying 
approach was adopted. Additionally, the exposure to gon-
adotoxic therapies reviewed was retrospectively. 
MATERIAL And METhOdS
A single-center cross-sectional study was carried out 
from December 2016 to January 2018. All subjects gave 
their informed consent for inclusion before they participated 
in the study. The study was conducted in accordance with 
the Declaration of Helsinki. The study population included 
childhood cancer survivors treated at the Center for Pedi-
atric Oncology and Hematology, Vilnius University Hospital 
Santaros Klinikos. The inclusion criteria were defined as 
1) age 18+ years as of December 2016; 2) childhood cancer 
(ICD-O-10 C00-C96) diagnosed in 1982-2011; 3) In remission 
5+ years since diagnosis in December 2016. The study was 
approved by the Vilnius Regional Committee of Biomedical 
Research (Approval No.158200-16-873-385).
Survivors who met the inclusion criteria were identi-
fied at the institutional database. The identified cohort was 
contacted by regular certificated mail to the postal address 
available in the medical records: an invitation to participate 
in the study, an informed consent form, and a questionnaire 
were sent to each consignee. The respondents who signed 
the informed consent, completed the questionnaire, and 
returned it to the study center were included into the final 
analysis. 
Two gender-specific questionnaires were elaborated 
by a multidisciplinary team of pediatric oncologist, obste-
trician-gynecologist, urologist and clinical embryologist. 
The participants were invited to answer 17–18 questions 
regarding sexual health, ability to conceive, marital sta-
tus/partnership (Supp. 1 available on https://journals.via-
medica.pl/ginekologia_polska/issue). As a complementary 
service a consultation of a gender-appropriate reproductive 
health specialist was offered to all contacted survivors. Ad-
ditionally, a summary of the study results was offered to be 
shared upon request.
The answers were collected from the completed ques-
tionnaires and analyzed anonymously. Baseline charac-
teristics and treatment-related data (diagnosis, type of 
chemotherapy drugs used and dosages, information on 
radiotherapy and surgical treatment) were retrieved from 
the patients’ paper or electronic medical records. 
The exposure to alkylating agents was assessed 
by CED calculation using the equation described by 
Green et al. [12]: CED (mg/m2) = 1.0 (cumulative cyclo-
phosphamide dose, mg/m2) + 0.244 (cumulative ifos-
famide dose, mg/m2) + 0.857 (cumulative procarbazine 
dose, mg/m2) + 14.286 (cumulative chlorambucil dose, 
mg/m2) + 15.0 (cumulative BCNU dose, mg/m2) + 16.0 (cumu-
lative CCNU dose, mg/m2) + 40 (cumulative melphalan dose, 
mg/m2) + 50 (cumulative thioteps dose, mg/m2) + 100 (cu-
mulative nitrogen mustard dose, mg/m2) + 8.823 (cumula-
tive busulfan dose, mg/m2). Cumulative treosulfan dose was 
not included in the original computation. The dacarbazine 
cumulative dose was calculated as a single drug — being 
quite different from other classical alkylating agents, it is 
not included in CED calculation. In addition, a cumulative 
dose of platinum compounds (carboplatin and cisplatin) 
was evaluated.  Data on the surgery and radiotherapy 
for potential involvement of gonadal areas were revised. 
The data evaluation time-point was January 2018.
Demographic and treatment-related characteristics 
were assessed using descriptive statistics. The median-test 
was used to compare the medians of cumulative CED be-
tween different types of childhood cancer. SPSS ver. 17 (IBM 
Corp., Armonk, NY) was used for all quantitative analyses, 
p-value less than 0.05 was considered to be significant.
RESuLTS
In total 346 childhood cancer survivors [195 (56.4%) 
males and 151 (43.6%) females] matched the inclusion 
criteria (Supp. 2 available on https://journals.viamedica.
pl/ginekologia_polska/issue). In contrast to the expecta-
tions, the response rate was very low – only 34 (9.8%) survi-
vors answered the questions. One hundred twenty (34.7%) 
consignees appeared to be unavailable: in 99 (28.6%) cases 
the letters were not reclaimed at the post office, in 19 (5.5%) 
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Table 1. Baseline characteristic of the study participants
Variables
Study participants





























Leukemia, myeloproliferative disorders, myelodysplasia n, (%) 
Lymphomas and reticuloendothelial neoplasms n, (%)
Tumors in the Central Nervous System n, (%)
Neuroblastoma and other peripheral nerve sheath tumors n, (%)
Osteosarcoma and other bone malignancies n, (%)



















*according to ICCC-3 (International classification of childhood cancer)
cases the postal address was no longer valid, 2 (0.6%) pa-
tients had died. However, the majority of the invited sur-
vivors 190 (54.9%) received the invitation but refrained 
from sharing their answers. None of them wished to take 
the opportunity to see a specialist in reproductive health.   
Thirty-four (9.8%) respondents (17 males and 17 fe-
males) were included into the final analysis. The median age 
at the time of evaluation was 27 (18–35) years, meanwhile 
the one at cancer diagnosis — 13 (2–18) years. The age did 
not differ between males and females (Tab. 1). Leukemia 
and lymphoma were the most common types of malignan-
cies among the respondents [13 (36.1%) and 15 (44.1%), 
respectively] whereas only 6 (17.6%) were affected by solid 
tumors. All patients were diagnosed with only one type of 
cancer, there were no cases of a second malignant neoplasm. 
The distribution of cancer types across survivors who met 
the inclusion criteria and were invited to participate in the 
study showed a slight predominance of leukemia as com-
pared to the study cohort: among 346 survivors, 165 (47.7%) 
were diagnosed with leukemia, 122 (35.3%) with lymphoma, 
and only 59 (17.1%) with solid tumors (Supp. 2  available 
on https://journals.viamedica.pl/ginekologia_polska/issue).
Most of the survivors were treated with chemotherapy 
(n = 33, 97%), radiotherapy was delivered to 18 patients 
(54.5%), six (17%) patients were operated on, and two 
patients received an allogeneic hematopoietic stem cell 
transplantation (HSCT) (Tab. 2). Treatment protocols varied 
according to the time period of the diagnosis and type of 
malignancy. The majority of leukemia patients were treated 
according to Berlin-Frankfurt-Münster (BFM) based protocols 
while one respondent was cured after being treated ac-
cording to the Nordic Society of Pediatric Hematology and 
Oncology (NOPHO) Acute Lymphoblastic Leukemia (ALL) 
2008 guidelines. The treatment protocols are indicated in the 
Table 2 and are outlined in details in the Supplement 3 (avail-
able on https://journals.viamedica.pl/ginekologia_polska/is-
sue). None of the survivors were irradiated on abdominal 
field, however nine respondents received cranial irradiation.
Review of the exposure to gonadotoxic drugs revealed 
significantly higher median cumulative CED in patients 
treated for solid tumors as compared to those treated for 
lymphoma and leukemia (6660 vs 4352 vs 3000 mg/m2, 
respectively, p = 0.014). According to the expectation in 
leukemia cohort CED was much higher in the recipients 
of allogeneic HSCT as compared to non-transplanted pa-
tients. Additionally, females affected by Hodgkin lympho-
mas were treated with dacarbazine (median cumulative 
dose was 2250 mg/m2) whereas platinum compounds were 
frequently added in solid tumors (the respective median cu-
mulative dose for carboplatin and cisplatin was 1500 and 
50 mg/m2, Tab. 2).
Perception of the reproductive health  
in males
The answers to the questions provided by the male sur-
vivors are summarized in Table 3. All 17 respondents were 
able to get an erection and ejaculate, two survivors (11.8%) 
reported problems with penetration (both were single at the 
time of evaluation). Ten young men (58.8%) were married 
or had a partner, the remaining seven (41.2%) were single 
at the time of assessment. The average sexual activity was 
three times per week (ranged from 0 to 10). The majority of 
males (94.1%) felt normal sexual desire, on a ten-point scale 
the average libido score was nine (ranged from 3 to 10). 
Thirteen survivors (76.5%) used contraception, preferably 
the barrier one. Notwithstanding, 14 out of 17 (82.4%) did 
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Table 3. Responses provided by the male survivors (n = 17)
Variable n (%)
Feel sexual desire
Feel low sexual desire
16 (94.1)
1 (5.9)
Able to get an erection
Unable to get an erection 
17 (100)
0 (0)
Able to ejaculate 
Unable to ejaculate 
17 (100)
0 (0)
Able to insert penis into vagina 
Unable to insert penis into vagina 
15 (88.2)
2 (11.8)




Sexual activities per week, median (min-max) 3 (0–10)
Libido*, median (min-max) 9 (3–10)
Do not use contraception 
Use contraception 
 Barrier contraceptives 
 Coitus interruptus 






Trying to conceive at the moment, 
Not trying to conceive at the moment 
3 (17.7)
14 (82.4)
Time trying to conceive (months), median (min-max) 1 (1–12)
Have biological children 
Do not have biological children 
4 (23.5)
13 (76.5)
Time to conceiving (months), median (min-max) 2 (1–16)
Partner has children 
Did not know if the partner has children 




Azoospermic in semen analysis 
Did not undergo semen analysis 
2 (11.8)
15 (88.2)
Received chemotherapy during adulthood
Received radiotherapy during adulthood




Close** relatives had fertility problems 
Close** relatives did not have fertility problems 
1 (5.9)
16 (94.1)
*scored from 1 to 10; **defined as grandfather, father, brother, cousin
not intend to conceive and did not have biological children 
(67.5%) at the time of the evaluation. The median time of 
conception after cessation of contraceptives in four males 
(23.5%) who had offspring was two months (range 1–16). 
Three males had one child each, one survivor had two 
healthy children. Two respondents (11.8%) underwent 
semen analysis, both were found to be azoospermic. Both 
were married or had a partner, one survivor was trying 
to conceive. One of the azoospermic males was treated 
for Ewing’s sarcoma, diagnosed at 15 years of age (CED 
35964 mg/m2), another one – for Hodgkin’s lymphoma, 
diagnosed at 12 years of age (CED 4571 mg/m2). Another 
patient reported concerns potentially affecting repro-
ductive health was chemo- and radiotherapy received 
beyond 18 years of age, one suffered from parotitis dur-
ing childhood and one male reported impaired fertility 
as a family problem. 
Table 4. Responses provided by the female survivors (n = 17)
Variables n (%)
Normal puberty
Delayed puberty  
15 (88.2)
2 (11.8)
Age of menarche, median (min-max) 14 (12–17)
Regular menstrual cycle  
Irregular menstrual cycle  
12 (70.6)
5 (29.4)
Have a partner  
Divorced    




Sexual activities per week, median (min-max) 1 (0–9)
Libido*, median (min-max) 5 (0–10)
Do not use contraception  
Use contraception  
Barrier contraceptives  
Hormonal contraceptives  
 Coitus interruptus  









Have biological children  
Do not have biological children  
7 (41.2)
10 (58.8)
Time to conceive (months), median (min-max) 3 (1–8)
Partner has children  
Partner does not have children  
The partner has never had another partner  





Experienced some fertility concerns  
No fertility problems  
2 (11.8)
15 (88.3)
Had gynecological problems  
Did not have gynecological problems  
3 (17.6)
14 (82.4)
Have been treated for infertility
Treated with hormonal replacement therapy




Received chemotherapy during adulthood  
Received radiotherapy during adulthood  




*scored from 1 to 10; **defined as sister, mother, grandmother
Perception of the reproductive health  
in females
The responses of female survivors are summarized in 
Table 4. Two (11.8%) out of 17 females reported delayed 
puberty. Median age of menarche was 14 (12–17) years 
— slightly delayed as compare to healthy Lithuanian pop-
ulation (13.5 years) [15]. Twelve (70.6%) participants had 
regular menstrual cycles, whereas 5 (29.4%) reported irregu-
lar bleeding. More than half of respondents (58.8%) were 
married or had a partner. Females reported median 1 (0–9) 
sexual activity per week, and 5 (0–10) points of libido on 
average. Seven (41.2%) survivors succeeded to conceive 
with a median time of conception was three [1–8] months 
after cessation of contraception. Eight (47.1%) females did 
not use any methods to avoid conception while the other 
half used different contraceptives (Tab. 4). The pregnan-
cies terminated in seven full term pregnancies and three 
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miscarriages. Only two (11.8%) females reported fertility 
problems. However, gynecological concerns such as pelvic 
adhesion, polycystic ovarian syndrome, uterine leiomyomas 
/fybroids were more frequent. One participant suffered/ 
from a sexually transmitted disease, another one underwent 
surgeries of the uterus or ovaries. None of the participants 
were treated for infertility or sought for assisted reproduc-
tion, hormonal replacement therapy (HRT) or had family 
history of infertility. Two (11.8%) females reported having 
received chemotherapy or radiotherapy beyond the age 
of 18. Four respondents took daily medicines: Two (11.8%) 
were taking L-Thyroxine (both of them had children), one 
— beta blockers, the fourth one was on immunoglobulin 
replacement therapy due to a secondary immune deficiency 
following HSCT.
dISCuSSIOn
The current study is the first attempt to address the 
quality of reproductive health in Lithuanian childhood 
cancer survivors. The crosscut survey aimed at capturing 
impairments of reproductive health in a specific cohort of 
childhood cancer survivors known to have long-term late 
effects related to cancer treatment.
The most relevant limitation of our study is a low number 
of survivors who reported their experiences. The obtained 
results derived only from 34 out of 346 (9.8%) addressed 
survivors who fulfilled the questionnaires. More than half 
of the consignees (190, 54.9%) received the questionnaire 
but did not wish to participate in the survey. This fact raises 
a concern of feasibility to address such a delicate issue as 
reproductive and sexual health in childhood cancer survi-
vors many years after treatment — the median follow-up 
of the respondents was 14 years. One could speculate that 
those who did have sexual or fertility worries were reluctant 
to disclose them or opted for the ‘right to be forgotten’ [16]. 
The stigma of cancer is still prevalent and many survivors 
prefer to avoid sharing their disease- or treatment-related 
experiences and its consequences. Some parents of very 
young children protected them from knowing that they 
were treated for cancer (personal experience), and presum-
ably did not inform them about the mailed invitation. Other 
studies reported a variable response rate to the question-
naires regarding the reproductive function in childhood 
cancer survivors – the percentage of responders varied 
from 29.3% to 78.6% [13, 17–21]. A low response rate may 
suggest a response bias and limited ability to generalize 
the results. On the other hand, many survivors pointed out 
insufficient information on the impact of cancer treatment 
on fertility and its preservation options [6, 21–23]. Raising 
awareness of potential fertility harm after completion of 
therapy would facilitate the assessment of reproductive 
health in the future.
Of note, one third (34.7%) of our survivors did not re-
ceive the mail due to demographic changes in the coun-
try – the emigration rate in Lithuania was the third high-
est in the European Union in 2017 [24], young emigrants 
(20–34 years) comprising the largest group [25]. A high 
number of citizens who left their home country reflected 
a global trend of extreme mobility of young people. Thus, 
a pan-European system of surveillance of pediatric cancer 
survivors such as Survivorship Passport [26] would enable 
to provide an appropriate and timely care to this vulner-
able population across Europe. The implementation of this 
digital tool translated to several European languages would 
facilitate access to the information on treatment and rec-
ommendations of care independently of the living place, 
at least in Europe. 
The second limitation of the study was a retrospec-
tive way to retrieve data on treatment. In contrast to the 
cancer type distribution in all survivors eligible for the 
study (n = 346) who were treated mostly for leukemia 
[n = 165 (47.7%), Supp. 2] in the responders’ cohort lym-
phoma was the predominant diagnosis [n = 15 (44.1%), 
Table 1]. The documentation analysis was limited to the 
study participants’ records. As a consequence, the treatment 
applied was quite heterogenous, especially in the solid 
tumor group. Thus, only a descriptive data review could be 
carried out. Nevertheless, even in such a small and heterog-
enous group we could demonstrate much higher exposure 
to gonadotoxic drugs expressed as a significantly higher 
median CED in solid tumors as compared to leukemia and 
lymphoma (p = 0.014) as well as more complex treatment. 
Although there is no data comparing median CEDs across 
different types of childhood cancer, some studies have 
shown that solid tumors, particularly sarcomas, are treated 
with a high-dose alkylating agent therapy, which is related 
to males’ infertility in the adulthood as well as treatment 
for Hodgkin lymphoma can cause infertility in males [17]. 
In our survey, the perception of sexual dysfunction among 
childhood cancer survivors was similar to that observed 
among healthy population: in males the rate of low sexual 
desire or difficulties in penetration did not exceed 11.2% that 
is comparable to the rate observed in young healthy Lithu-
anian males [27]. The results differ from data reported by other 
groups showing high prevalence of sexual dysfunction in 
childhood cancer survivors [28, 29]. The inconsistency is most 
probably attributable to a non-response bias as discussed 
above. There are no data on exact prevalence of infertility 
among healthy Lithuanian population. Datta et al., reported 
an infertility rate of 12.5% among healthy women and 10.1% 
among men in Britain [30]. According to World Health Or-
ganization, global infertility prevalence rates are difficult to 
determine, however, approximately one in every four couples 
in developing countries had been found to be affected by 
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infertility [31]. Specifically, adult cancer survivors encounter 
reproductive health worries as well – womens’ pregnancy 
rates are quite low [32]. It seems that the adverse effect of sys-
temic treatment was strongly related with a patient’s age [33], 
therefore childhood cancer survivors are exposed at increased 
risk of infertility. Males are in a higher risk for hypogonadism 
and sexual dysfunction [34]. Both male and female survivors 
lacked knowledge about infertility and underestimated the 
risk of infertility [35]. In our study only few males had bio-
logical children and attempted to conceive probably due to 
the young age of the respondents (median current age was 
25 years). However, in this small cohort study, two males were 
azoospermic, both were treated with high cumulative doses 
of gonadotoxic drugs, CED ≥ 4000 mg/m2, which is known 
to be related to impaired spermatogenesis [17]. 
The percentage of men having low semen quality in 
male childhood cancer survivors (11.8%) are in parallel with 
semen quality of young men from the general population 
in Baltic countries (11–15% of them have low semen qual-
ity) [36]. Our study replicated the data published by other 
study groups who found that infertility was most prevalent 
among male survivors treated for sarcomas and Hodgkin 
lymphoma. In addition, the risk of permanent sterility was 
especially high when the cumulative dose of cyclophos-
phamide was greater than 7.5 g/m2 [17, 37]. This finding 
raises a concern that the number of azoospermic survivors 
could be higher if semen analysis was offered as a routine 
follow-up investigation and points out on the relatively easy 
preservation of fertility in male adolescents.
Only a few of female participants reported delayed pu-
berty, fertility-related or gynecological problems. None of 
the respondents was treated for infertility or used HRT, 
with 29.4% reported an irregular menstrual cycle. Few stud-
ies investigated the age of menarche of childhood cancer 
survivors. Some findings suggested that childhood cancer 
treatment including cranial radiation in girls resulted in a sig-
nificantly earlier menarche [38]. Other stated that cranial 
irradiation appeared to have a minimal impact on the onset 
of puberty [39]. However, survivors of the central nervous 
system tumors appeared to be at significant risk of both 
early and late menarche associated with radiotherapy [40]. 
Our study did not include a comparison group, it would be 
insightful to compare reproductive health of survivors with 
their healthy siblings as it was done in some other studies 
[14, 41]. Data from other studies showed that female sur-
vivors are at a future risk of premature menopause (before 
40 years) [42–44], they also had an increased risk of clinical 
infertility (> 1 year of attempts at conception without suc-
cess) compared to siblings [41]. Our current study did not 
include a hormonal analysis that could have given a better 
estimation of the prevalence of sexual dysfunction. Other 
similar studies found that cancer survivors had significantly 
lower anti-Müllerian hormone and higher follicle-stimulat-
ing hormone levels [19, 45–48].
In addition, psychosexual and social problems of child-
hood cancer survivors could be taken into account as they 
were reported in other studies, such as lower rates of mar-
riage and parenthood, delayed sexual intercourse, and 
concerns regarding the reproductive function [49, 50]. As 
the study included the survivors treated more than a dec-
ade ago, none of them was appropriately informed about 
the impact of the treatment on reproductive health. 
The availability of fertility preservation techniques was quite 
limited at that time. Due to the dramatic changes occurred 
in current practice, prospective counseling on fertility pres-
ervation must be offered to all patients and their families. 
COnCLuSIOnS
To summarize, we found a low prevalence of sexual dys-
function, fertility related or puberty disorders in childhood 
cancer survivors, however, considering a low response rate, 
the results should be interpreted with caution. Potential 
azoospermia after high CED in male patients should imply 
mandatory fertility preservation before treatment whenever 
possible. This study is the first attempt to address the quality 
of reproductive health in Lithuanian childhood cancer sur-
vivors that unraveled important concerns to be improved in 
clinical practice. Implementation and equal access to fertility 
preservation techniques (e. g. cryopreservation of semen 
and ovarian tissue) should be prioritized to minimize ad-
verse effect of infertility after cancer therapy. An appropriate 
counseling of all cancer patients and families on potential 
adverse effect of the treatment on reproductive health would 
facilitate a highly warranted prospective research in a larger 
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